Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)

Men with circulating tumor cell (CTC) AR-V7 positive mCRPC have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive-biomarkers are needed. We conducted a retrospective secondary analysis of the prospective PROPHECY trial (N...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Res
Autori principali: Gupta, Santosh, Halabi, Susan, Kemeny, Gabor, Anand, Monika, Giannakakou, Paraskevi, Nanus, David M., George, Daniel J., Gregory, Simon G., Armstrong, Andrew J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178231/
https://ncbi.nlm.nih.gov/pubmed/33771885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-20-0975
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi